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Rh discrepancies are a problem during routine testing because of 
partial D or weak D phenotypes. Panels of monoclonal antibodies 
(MoAb) are being developed to identify D variants such as partial D 
and weak D when there are anomalous D typing results; however, 
molecular characterization offers a more specific classification 
of weak and partial D. The weak D and partial D phenotypes 
are caused by many different RHD alleles encoding aberrant 
D proteins, resulting in distinct serologic phenotypes and the 
possibility of anti-D immunization. We evaluated currently used 
serologic methods and reagents to detect and identify D variants 
and correlated the results with molecular analyses. A total of 306 
blood samples from Brazilian blood donors and patients with 
discrepant results in routine D typing were analyzed. In total, 166 
(54.2%) weak D, 136 (44.4%) partial D, 3 (1%) DEL, and 1 (0.3%) 
DHAR variants were identified. Among weak D samples, 76 weak 
D type 1 (45.8%), 75 weak D type 2 (45.2%), 13 weak D type 3 
(7.8%), and 2 weak D type 5 (1.2%) alleles were found. Among 
the partial D samples, 49 type 4.0 weak partial D (36%), 9 DAR 
(6.6%), 24 DFR (17.6%), 6 DBT (4.4%), 1 DHMi (0.73%), 26 DVI 
(19%), 14 DVa (10.3%), 5 DIVb (3.7%), and 2 DVII (1.5%) were 
observed. Two samples identified as DEL by adsorption-elution 
were characterized by molecular analyses as RHD(IVS5–38DEL4) 
and one sample was characterized as RHD(K409K). One sample 
was characterized as DHAR, a CE variant positive with some 
monoclonal anti-D. Our results showed that the use of different 
methods and anti-D reagents in the serologic routine analysis 
revealed D variants that can be further investigated. Molecular 
methods can help to differentiate between partial D and weak 
D and to characterize the weak D types, providing additional 
information of value in the determination of D phenotypes. This 
distinction is important for optimized management of D– RBC 
units and for the prevention of anti-D–related hemolytic disease 
of the fetus and newborn. Immunohematology 2011;27:6–11.
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Rh epitopes are highly conformational, and single 
amino acid changes in one part of the protein, including 
changes within the transmembrane regions, can affect 
expression of epitopes or result in new epitopes. Single 
nucleotide polymorphisms (SNPs) and gene conversions 
between the RHD and RHCE genes are primarily 
responsible for the large number of variations in expression 
of the Rh antigens.1,2
The D antigen is the most important blood group 
antigen determined by a protein, because D– individuals 
can be easily immunized to make anti-D. A plethora of 
RHD alleles have been identified at the molecular level, 
including those that encode partial D, and weak D types, 
and a particularly weakly expressed D antigen termed DEL, 
that can only be demonstrated by adsorption and elution.3–9
Weak D phenotypes are characterized by depressed 
expression of the D antigen, and at the molecular level, D 
variants are caused by many different RHD alleles carrying 
single or multiple missense mutations in their RHD coding 
sequences encoding altered D proteins.3,4,6 No alloanti-D has 
been found in individuals with the most common weak D 
types (1, 2, and 3); however, little is known about the anti-D 
immunization risk in people with the rare RHD alleles with 
lower antigen density than weak D type 2.4,10 Weak D types 
generally present all epitopes albeit with some epitopes 
showing variability depending on the monoclonal anti-D 
used for testing.11 The classification of variants as weak 
D does not imply that carriers will not be immunized by 
exposure to normal D through transfusion or pregnancy as 
weak D types 4.0, 4.2, 11, and 15 were described to be prone 
to anti-D alloimmunization and thus should be considered 
as partial D.4,11–15 Partial D variants lack D antigen epitopes, 
and individuals who harbor partial D variant alleles have 
the potential to make alloanti-D.8 Anti-D immunization 
was also attributed to patients transfused with red blood 
cell (RBC) units from DEL donors.9
The differentiation and identification of D variants is 
important for selection of blood products and to prevent 
anti-D-related hemolytic disease of the fetus and newborn; 
however, it is not always straightforward, and, occasionally, 
phenotype discrepancies occur between two reagents.11,16,17
Populations with African admixture, such as the 
Brazilian population, can present a high variety of RHD 
alleles.18 A comprehensive investigation of the RHD alleles 
that encode weak D expression at the RBC surface could 
have a considerable impact on the typing and transfusion 
strategy in countries like Brazil where the prevalence 
of D– phenotypes ranges from 5 percent to 12 percent 
Serologic and molecular characterization of 
D variants in Brazilians: impact for typing and 
transfusion strategy
D.C. Credidio, J. Pellegrino Jr., and L. Castilho
Case RepoRt
IMMUNOHEMATOLOGY, Volume 27, Number 1, 2011 7
D variants in Brazilians
approximately. The use of different methods and anti-D 
reagents in the routine serologic analysis has revealed 
some D variants that are being investigated by molecular 
methods. We here describe the serology and molecular 
analyses performed to identify such variants among 




Blood samples, collected over a 2-year period, from 
306 Brazilians (117 blood donors and 189 patients) with 
discrepant results of D typing with different commercial 
anti-D monoclonal antibodies (MoAbs), or weak reactivity 
(<3+ at room temperature or reactivity in indirect 
antiglobulin test [IAT] only) were referred by routine 
laboratories from different regions of Brazil to our 
laboratory for molecular characterization and transfusion 
counseling. D typing in the referring laboratories was 
performed with two different anti-D MoAbs in conjunction 
with IAT as is required in Brazil for donors and patients as 
a result of the deficit of D– RBC units.
Serologic Studies
D, C, E, c, and e status of all RBCs was determined by 
hemagglutination in gel neutral cards (DiaMed AG, Cressier 
sur Morat, Switzerland) using routine anti-D, anti-C, 
anti-E, anti-c, and anti-e monoclonal reagents (Fresenius 
Kabi, São Paulo, Brazil). D-antigen reactivity was analyzed 
by agglutination in tube and gel cards using six anti-D 
monoclonal reagents: anti-D IgM (clone 175–2) and anti-D 
IgG (clone ESD1; DiaMed AG); IgM (clone P3X61) and anti-D 
Blend (clones P3X290, P3X35, P3X61, P3X21223B10; 
Grifols, Barcelona, Spain); and anti-D IgM (clone MS201) 
and anti-D IgG (clone MS26; Smart Kit, Fresenius Kabi). 
Nonreactive samples were tested with anti-D blend (clones 
MS26/MS201) and anti-D IgG (clone ESD1) using the IAT in 
tube and two gel matrix techniques (DiaMed and Grifols). 
An adsorption-elution test was performed on samples that 
were nonreactive in the IAT and expressed the C antigen.
PCR Assays
DNA was extracted from whole blood samples using 
the QIAmp DNA Blood Mini-Kit (Qiagen, Valencia, CA), 
according to the manufacturer’s recommendations. 
Two polymerase chain reaction (PCR) assays were used 
to determine the presence or absence of RHD-specific 
amplified products from sequences in intron 4 and exon 7.19 
The other assays used were a PCR system using sequence-
specific primers (SSP) that detect the common weak D 
types,6 a multiplex PCR20 that detects the RHD gene hybrid 
alleles, and specific PCR–restriction fragment length poly-
morphisms (RFLP) to distinguish between weak D type 
4.2.2 and DAR alleles.21 Table 1 summarizes the RHD alleles 
investigated and the polymorphisms detected.
Sequence Analysis
Sequence analysis was performed to confirm the DEL 
phenotypes found by adsorption-elution on PCR products 
amplified from genomic DNA using RHD-specific primers 
as previously reported.3 PCR products were purified by 
elution from 1 percent agarose gels using a Qiaex II gel 
extraction kit (Qiagen) and sequenced directly, without 
subcloning, on an ABI 373XL Perkin Elmer Biosystems 
(PEB) sequencer using the PEB Big Dye reagent BD Half-
term (GenPak, Perkin Elmer Biosystems, Foster City, CA).
Results
During a 2-year period blood samples from 117 blood 
donors and 189 patients with discrepant results or weak 
reactivity with two monoclonal anti-D reagents in routine 
diagnostics were tested by hemagglutination with currently 
used MoAbs in Brazil and by molecular analyses. Although 
we have separated those two populations (patients and 
donors) in this study, they are comparable in terms of ethnic 
background in Brazil.
Molecular Analyses
In total, 166 weak D (54.2%), 136 partial D (44.4%), 
3 DEL (1%), and 1 DHAR (0.3%) variants were identified. 
Tables 2 and 3 summarize the distribution of weak D 
and partial D alleles and the associated haplotypes. The 
weak D types 1, 2, and 3 were the most prevalent weak D 
types found in this population. Weak D types 1 and 3 were 
associated with the DCe and Dce haplotypes, and weak D 
type 2 was associated with DcE .
Serologic Reactivity
Six selected monoclonal anti-D (IgG, IgM, and blend) 
were used in tube and gel to evaluate the reactivity pattern 
of these monoclonal anti-D reagents with D variants. The 
reactivity with the monoclonal anti-D reagents showed a 
generally consistent pattern among the variant RHD alleles 
that occurred more than once. Table 4 summarizes the 
results found in the donor and patient samples studied. 
Weak D types 1 and 3 and weak partial D type 4.0 and 
partial D DBT were detected with all anti-D MoAbs  in tube 
and gel. Weak D types 2 and 5 and partial D DAR, DFR, 
DHMi, and DVI were not detected with the IgM monoclonal 
anti-D antibodies, whereas DIVb was not detected with 
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anti-D IgG. Weak D type 2 and partial D DVI type 1 showed 
the same pattern of reactivity with the six monoclonal 
anti-D used.
Sequence Analysis
To confirm the DEL phenotype results obtained by 
adsorption-elution, we performed sequence analysis of 
the RHD from three DNA samples. Two donor samples 
were characterized by molecular analyses as RHD(IVS5–
38DEL4) and one patient sample was characterized as 
RHD(K409K).
Discussion
We report a serologic and molecular study of D 
variants in Brazilians who were identified because of weak 
or discrepant D typing results with different commercial 
monoclonal anti-D reagents and show that a high percentage 
(44%) of them are partial D, including the weak partial D 
type 4.0. Seventy-seven partial D variants (56.6%) were 
from patients, and 5 of them (3 partial D category VI type 
2, 1 partial D DAR, and 1 partial D category Va) already had 
alloanti-D in their serum. Many partial D variants were 
classified as weak D owing to variable reactivity with the 
anti-D MoAb used.
Table 1. Molecular basis of D variants and polymorphisms detected in this study
RHD allele Molecular basis Polymorphisms detected
RHD*weak D type 1 809T>C 809T>C
RHD*weak D type 2 1154G>C 1154G>C
RHD*weak D type 3 8C>G 8C>G
RHD*weak D type 4.0 602C>G, 667T>G, 819G>A 602C>G, 819G>A
RHD*weak D type 4.1 48G>C, 602C>G, 667T>G, 819G>A 48G>C, 602C>G, 819G>A
RHD*weak D type 4.2.2 602C>G, 667T>G, 744C>T, 1025T>C 602C>G, 667T>G, 744C>T, 1025 T>C
RHD*weak D type 5 446C>A 446C>A
RHD*DAR 602C>G, 667T>G, 1025T>C 667T>G,744C>T, 1025T>C
RHD*DFR 505A>C, 509T>G, 514A>T
(RHCE-like segment encompassing part of exon 4)
505A>C, 509T>G, 514A>T
RHD*DBT 667T>G, 697G>C, 712G>A, 733G>C, 744C>T, 787G>A, 800A>T,  
916G>A, 932A>G, 941G>T, 968C>A, 974G>T, 979A>G, 985G>C,  
986G>A, 989A>C, 992A>T, 1025T>C, 1048G>C, 1053C>T, 1057G>T, 
1059A>G, 1060G>A, 106C>A
(RHCE-like segment encompassing exons 5 to 7)
RHD exon scanning:  
exons 5 to 7 negative
RHD*DHMi 848C>T 848C>T
RHD*DIVb 104G>C, 1053C>T, 1057G>T, 1059A>G, 1060G>A, 1061C>A, 1170C>T, 
1193A>T
(RHCE-like segment encompassing part of exon 7 to exon 9)
RHD exon scanning:  
exons 7 and 9 negative
RHD*DVa 667T>G, 697G>C, 733G>C, 744C>T, 787G>A, 800A>T
(RHCE-like segment encompassing exon 5)
RHD exon scanning:  
exon 5 negative
RHD*DVI.1 505A>C, 509T>G, 514A>T, 544T>A, 577G>A, 594A>T, 602C>G, 667T>G, 
676G>C, 697G>C, 712G>A, 733G>C, 744C>T, 787G>A, 800A>T
(RHCE-like segment of CE-allele encompassing exons 4 to 5
RHD exon scanning:  
exons 4 and 5 negative
RHD*DVI.2 505A>C, 509T>G, 514A>T, 544T>A, 577G>A, 594A>T, 602C>G, 667T>G, 
697G>C, 712G>A, 733G>C, 744C>T, 787G>A, 800A>T, 916G>A, 932A>G
(RHCE-like segment encompassing exons 4 to 6)
RHD exon scanning:  
exons 4 to 6 negative
RHD*DVII 329T>C 329T>C
Table 2.  Weak D types and associated haplotypes found in blood 
donor and patient samples
Weak D types
Samples Haplotypes Type 1 Type 2 Type 3 Type 5 Total
Blood 
donors
Dce 4 2 6
DCe 33 4 2 39
DcE 22 22
Total 37 22 6 2 67
Patients Dce 3 3 6
DCe 36 4 40
DcE 53 53
Total 39 53 7 99
Total of 
samples
Dce 7 5 12
DCe 69 8 2 79
DcE 75 75
Total 76 75 13 2 166
% 45.8 45.2 7.8 1.2
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This 44 percent value corresponds to a prevalence 
study in a population with a D variant phenotype and not 
to the ratio between the number of RHD alleles known to 
encode a partial and weak D and the total number of weak 
RHD alleles described. That is the reason why our results 
differ from other results reported, that approximately 5 to 
10 percent of weak D are partial D.3,4,11,22
In our study weak D type 2 and D category VI type 
1 showed a similar reactivity pattern with the anti-D 
used, despite their different molecular background. 
The IgM anti-D used do not detect DVI, whereas the 
IgG anti-D detect DVI. As observed in Table 4, the IgM 
anti-D failed to react with weak D type 2 and DVI type 
1, and the patterns of reactivity with the other anti-D 
used were similar in tube and in gel. One explanation 
for these results may be the difference in the ability of 
the IgG anti-D MoAb and blend IgG + IgM anti-D to 
detect “weak D phenotypes” compared with that of the 
IgM anti-D. This finding reinforces that there is no well-
defined borderline between weak D and some partial D 
phenotypes that express the D antigen weakly (partial 
weak D phenotype) that have an aberrant RHD coding 
sequence,3 and therefore a PCR screen for those variants 
should be recommended.
Table 3.  Partial D and associated haplotypes found in blood donor and patient samples
Partial D
Samples Haplotypes Type 4.0 DAR DFR DBT DHMi DVI DVa DIVb DVII Total
Blood donors Dce 21 1 3 25
DCe 5 3 1 12* 21
DcE 1† 1
Total 21 1 5 3 1 13 3 0 0 47
Patients Dce 28 8 1 11 2 50
DCe 16 2 13* 5 36
DcE 3 3
Total 28 8 19 3 0 13 11 5 2 77
Total of samples Dce 49 9 1 59
DCe 21 5 1 25* 14 5 71
DcE 3 1† 4
Total 49 9 24 6 1 26 14 5 2 136
% 36 6.6 17.6 4.4 0.73 19 10.3 3.7 1.5
*DVI type II. †DVI type I.
Table 4. RHD alleles and reactivity with monoclonal anti-D reagents
MoAbs × reactivity
Tube Gel DiaMed Gel Grifols
Samples RHD Alleles MS201 MS26+MS201
P3X35/ 





76 RHD*weak D type 1 1+ 2+ 3+ 1+ 2+ 3+ 2+ 3+ 3+
75 RHD*weak D type 2 0 0 1+ 0 (+) 1+ 0 1+ 2+
13 RHD*weak D type 3 2+ 3+ 3+ 3+ 2+ 3+ 3+ 3+ 4+
2 RHD*weak D type 5 0 0 (+) 0 0 1+ 0 1+ 2+
49 RHD*weak partial 4.0 2+ 3+ 3+ 3+ 2+ 3+ 2+ 3+ 3+
9 RHD*DAR 0 1+ 2+ 0 1+ 2+ 0 1+ 2+
24 RHD*DFR 0 1+ 2+ 0 2+ 3+ 0 2+ 3+
6 RHD*DBT 1+ 1+ 2+ 2+ 2+ 3+ 3+ 2+ 3+
1 RHD*DHMi 0 1+ 2+ 0 1+ 2+ 0 2+ 3+
5 RHD*DIVb 2+ 1+ 3+ 2+ 0 3+ 2+ 1+ 2+
14 RHD*DVa 2+ 2+ 3+ 1+ 1+ 2+ 2+ 1+ 2+
25 RHD*DVI.1 0 0 1+ 0 1+ 2+ 0 1+ 2+
1 RHD*DVI.2 0 1+ 2+ 0 2+ 2+ 0 2+ 3+
2 RHD*DVII 0 2+ 3+ 1+ 2+ 3+ 2+ 3+ 3+
(+) = weak. MoAbs = monoclonal antibodies.
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Among the weak D samples, 164 of 306 (53.6%) were 
categorized as weak D types 1, 2, and 3 with the molecular 
assays, and for those individuals D+ transfusion could be 
considered safe because no immunization events have been 
documented yet.4 Such a strategy is estimated to reduce the 
use of D– blood by 2 to 3 percent. The high prevalence of 
weak D types 1, 2, and 3 was consistent with other studies 
in Europe.3,4 In our population we see a higher prevalence 
of weak partial D type 4.0 (36%), perhaps because of the 
marriage among Caucasians, Amerindians, and Africans 
that occurred in our population. For the partial D, we 
also observed a higher prevalence of DAR, DFR, and DVa, 
reinforcing that the ethnic background of the population 
may govern which variants are prevalent.
Weak D and partial D and the associated haplotype 
found in this study were consistent with those found 
in other studies,3 although we have also found the Dce 
haplotype associated with weak D types 1 and 3 (Table 2). 
Unfortunately, we did not have enough DNA to sequence 
the full RHD on those samples, and further studies are 
necessary to confirm this finding.
The three samples identified as DEL by adsorption 
and elution exhibited known DEL alleles, RHD(IVS5–
38DEL4) and RHD(K409K). Donor RBC units from such 
individuals have been described before as inducing anti-D 
alloimmunization in D– patients.5,9 Taking these results into 
account, we recommend performing molecular analyses on 
donor samples phenotyped as D– C+ but D+ by adsorption 
and elution to identify the DEL allele and avoid immunization.
The sensitivity of the method used to type donor and 
patients may depend on the anti-D reagent used and on 
the exact conditions of the methods. For donor typing all 
potentially immunogenic D+ samples should be recognized 
as D+, and based on this we propose the use of two anti-D 
reagents (one anti-D blend and one IgM anti-D) to minimize 
the need for the IAT on donor samples. Because anti-D 
immunization may pose a serious clinical problem mainly 
in women of childbearing age, we propose that two different 
anti-D reagents (one IgM anti-D that does not detect DVI and 
one IgG anti-D that detects DVI) be used routinely to establish 
the Rh status for obstetric patients and transfusion recipients. 
When a discrepancy occurs between the two reagents, we 
recommend that molecular analysis is performed to identify 
the RHD allele. This strategy of combining serologic and 
molecular typing can provide a better solution to accurately 
determine the D-antigen status .
Finally, this study is of interest from a genetic and 
population perspective because it gives insight into the 
diversity of the RHD alleles in Brazilians. It is important 
to remember that much of the recent data on weak D and 
partial D have come from Europe.
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